Shots:
- Study 2 of the P-III SELECT-AXIS 2 clinical trial evaluates the efficacy & safety of upadacitinib (qd, 15mg) vs PBO in 314 adults with active nr-axSpA
- The trial met its 1EPs of ASAS40 response & 2EPs @14wks., patients achieved ASAS40 response & ASDAS low disease activity (45% vs 23%) & (42% vs 18%), reductions in signs & symptoms including back pain & inflammation, improvements in physical function (-2.61 vs -1.47) @14wks.
- Additionally, improvement in MRI SPARCC score (-2.49 vs 0.57); mean change from baseline in patient’s assessment of total back pain (-2.91 vs -2.00), safety data were consistent with previous studies & known safety profile of the therapy, no new risks were observed
Click here to read full press release/ article | Ref: AbbVie | Image: Fierce Biotech
The post AbbVie’s Rinvoq (upadacitinib) Met Primary and Secondary Endpoints in P-III SELECT-AXIS 2 Clinical Trial for Non-Radiographic Axial Spondyloarthritis first appeared on PharmaShots.
